TILRAY BRANDS INC (TLRY)
US88688T1007 - Common Stock
Overall TLRY gets a fundamental rating of 3 out of 10. We evaluated TLRY against 198 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
TLRY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TLRY has a better Return On Assets (-8.35%) than 74.36% of its industry peers.
The Return On Equity of TLRY (-10.48%) is better than 79.49% of its industry peers.
TLRY's Return On Invested Capital of 1.55% is fine compared to the rest of the industry. TLRY outperforms 78.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROIC | 1.55% |
ROA(3y)-23.71%
ROA(5y)-23.46%
ROE(3y)-42.39%
ROE(5y)-54.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of TLRY (10.30%) is better than 83.59% of its industry peers.
Looking at the Gross Margin, with a value of 28.01%, TLRY is in line with its industry, outperforming 51.79% of the companies in the same industry.
TLRY's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-15.87%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TLRY is destroying value.
TLRY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
TLRY has an Altman-Z score of 0.38. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
TLRY's Altman-Z score of 0.38 is in line compared to the rest of the industry. TLRY outperforms 54.87% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that TLRY is not too dependend on debt financing.
TLRY's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. TLRY outperforms 48.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.38 |
ROIC/WACC0.2
WACC7.85%
2.3 Liquidity
A Current Ratio of 1.92 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY's Current ratio of 1.92 is on the low side compared to the rest of the industry. TLRY is outperformed by 66.67% of its industry peers.
A Quick Ratio of 1.18 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY's Quick ratio of 1.18 is on the low side compared to the rest of the industry. TLRY is outperformed by 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
TLRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 87.83%, which is quite impressive.
TLRY shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.66%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.21% yearly.
EPS 1Y (TTM)87.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q93.68%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y98.21%
Revenue growth Q2Q29.35%
3.2 Future
The Earnings Per Share is expected to grow by 15.33% on average over the next years. This is quite good.
TLRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.94% yearly.
EPS Next Y90.13%
EPS Next 2Y39.84%
EPS Next 3Y25.27%
EPS Next 5Y15.33%
Revenue Next Year33.01%
Revenue Next 2Y21.64%
Revenue Next 3Y18.07%
Revenue Next 5Y17.94%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TLRY is valued cheaper than 93.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.34 |
4.3 Compensation for Growth
TLRY's earnings are expected to grow with 25.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.84%
EPS Next 3Y25.27%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TILRAY BRANDS INC
NASDAQ:TLRY (4/22/2024, 7:00:01 PM)
Premarket: 1.72 0 (0%)1.72
-0.01 (-0.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.33B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -10.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.3% | ||
| PM (TTM) | N/A | ||
| GM | 28.01% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.66%
Revenue growth 3Y55.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y